S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Keryx Drug Fails Test, Shares Plunge (KERX)

Photo of Paul Ausick
By Paul Ausick Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) this morning announced that its colorectal cancer treatment did no better than placebo in a Phase 3 trial. The company said it will evaluate whether or not to continue the Phase 3 trials of the drug.

Keryx also noted that it has $31 million in cash and plans to complete a Phase 3 study on an end-stage renal disease treatment in the fourth quarter. The company also plans to file a new drug application for the drug, called Zerenex, “shortly thereafter.”

The company’s stock is getting thrashed in the pre-market, down about -55% at $2.28, only a penny higher than its current 52-week low.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Dave Ramsey to Wife Who Caught Husband Lying About Debt 4 Times: '41 Years Down the Toilet'
Joel South |

Dave Ramsey to Wife Who Caught Husband Lying About Debt 4 Times: '41 Years Down the Toilet'
Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)
Jeremy Phillips |

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

Continue Reading

Douglas A. McIntyre |

Keryx Joins Biotech Zombie Ranks (KERX)

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) may have just joined the ranks of a biotech zombie, even if it doesn’t want…
Lee Jackson |

Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015

A new report from the biotech team at Deutsche Bank fields questions from clients asking for specific stocks to buy…
Jon C. Ogg |

Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More

The team at Oppenheimer has a list of biotech stocks to buy that feature catalysts that could be game changers.…
Jon C. Ogg |

BioHealth Business Daily (ARQL, APPY, BPAX, BMY, CLDX, CELG, DCTH, JAV, KERX, PCYC, TLCR, VVUS)

Today’s edition of the BioHealth Business Daily is going to be very cancer-dominated due to the American Society of Clinical…
Chris Lange |

Aclaris Gets Ready For Its Initial Public Offering

ThinkstockAclaris Therapeutics, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO).…
Chris Lange |

vTv Therapeutics Sets Expected Price Range for IPO

vTv Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
BioXel Gears Up for IPO
Chris Lange |

BioXel Gears Up for IPO

Clinical-stage biopharmaceutical company BioXel Therapeutics has filed with the SEC regarding its initial public offering.
Paul Ausick |

Peregrine Pharma Collapses on News of Data Errors

Just over two weeks ago Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) reported a statistically significant improvement in the company’s bavituximab lung-cancer…
Chris Lange |

Aclaris Enters Market Well Below Expected Range in IPO

Aclaris Therapeutics debuted on the market in its initial public offering (IPO) on Wednesday morning.

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618